As KRAS mutations are found in approximately 95% of cases of pancreatic cancer, it is considered that matched therapy (therapy that matches the genetic abnormality) is indicated in a small number of cases, but these results suggest that NGS testing to find actionable mutations should be performed early in the treatment process. Here, KRAS is linked to familial pancreatic carcinoma.